VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Healthy male and/or female subjects between the    │ Healthy male and/or female subjects between the    │     100 │
│ ages of 18 and 55 years, and a body mass index     │ ages of 18 and 55 years, and a body mass index     │         │
│ (BMI) of ≥ 18 and ≤ 33 kg/m2 with body weight ≥ 50 │ (BMI) of ≥ 18 and ≤ 33 kg/m2 with body weight ≥ 50 │         │
│ and ≤ 90 kg at screening                           │ and ≤ 90 kg at screening                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females must have been surgically sterilized       │ Females must have been surgically sterilized       │     100 │
│ (hysterectomy, bilateral oophorectomy, or          │ (hysterectomy, bilateral oophorectomy, or          │         │
│ bilateral salpingo-oophorectomy; proper            │ bilateral salpingo-oophorectomy; proper            │         │
│ documentation required) at least 6 months before   │ documentation required) at least 6 months before   │         │
│ screening, or be postmenopausal (defined as 24     │ screening, or be postmenopausal (defined as 24     │         │
│ consecutive months without menses before           │ consecutive months without menses before           │         │
│ screening, with a follicle-stimulating hormone     │ screening, with a follicle-stimulating hormone     │         │
│ \[FSH\] level of \> 40 IU/L at screening)          │ [FSH] level of > 40 IU/L at screening)             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Exposure/treatment to an investigational (new      │ Exposure/treatment to an investigational (new      │     100 │
│ chemical entity) or marketed drug or biologic      │ chemical entity) or marketed drug or biologic      │         │
│ within 30 days preceding the first dose            │ within 30 days preceding the first dose            │         │
│ administration, or five half-lives of that         │ administration, or five half-lives of that         │         │
│ investigational drug or biologic, if known         │ investigational drug or biologic, if known         │         │
│ (whichever is longer)                              │ (whichever is longer)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Donation blood or serum within 8 weeks before the  │ Donation blood or serum within 8 weeks before the  │     100 │
│ first dose administration to a blood bank or blood │ first dose administration to a blood bank or blood │         │
│ donation center                                    │ donation center                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of alcohol or drug abuse (as defined by    │ History of alcohol or drug abuse (as defined by    │     100 │
│ the current version of the DSM) within 2 years     │ the current version of the DSM) within 2 years     │         │
│ before the first dose administration, or positive  │ before the first dose administration, or positive  │         │
│ alcohol or drug screen                             │ alcohol or drug screen                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Vaccination within 30 days prior to the first dose │ Vaccination within 30 days prior to the first dose │     100 │
│ administration or has plans to receive a           │ administration or has plans to receive a           │         │
│ vaccination during the course of the study         │ vaccination during the course of the study         │         │
│ (including the follow phone call on Day 105)       │ (including the follow phone call on Day 105)       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 55 Years │ Healthy male and/or female subjects between the    │      23 │
│                                   │ ages of 18 and 55 years, and a body mass index     │         │
│                                   │ (BMI) of ≥ 18 and ≤ 33 kg/m2 with body weight ≥ 50 │         │
│                                   │ and ≤ 90 kg at screening                           │         │
├───────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Donation blood or serum within 8 weeks before the  │      24 │
│                                   │ first dose administration to a blood bank or blood │         │
│                                   │ donation center                                    │         │
╘═══════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 80.875
OverAll Ratio: 88.9375
